Pulido ZT

Language: Spanish
References: 8
Page: 142-144
PDF size: 32.12 Kb.

ABSTRACT

Primary pulmonary hypertension (PPH) is a rare, progressive and fatal condition. Because of nonspecific signs and symptoms, patients diagnosed with PPH are often present with a relatively advanced disease. Significant advances have been made in recent years. A revised nomenclature has been proposed, the pathobiology is now better defined, new risk factors have been identified, and the newer therapeutic strategies appear to be changing the natural history and prognosis of this disease.

REFERENCES

1. TUDER RM, LEE SD, COOL CC: Histopathology of Pulmonary Hypertension. Chest 1998; 114: 1S-6S.

2. RUBIN LJ: Primary Pulmonary Hypertension. N Engl J Med 1997; 336: 111-117

3. RICH S (ED): Primary Pulmonary Hypertension: Executive summary from the World Symposium on PPH, 1998. http://www.who.int/ncd/cvd/pph.htlm

4. GALIE N, MANES A, UGUCCIONI L, SERAFINI F, DE ROSA M, BRANZI A, ET AL: Primary Pulmonary Hypertension. Insights into pathogenesis from epidemiology. Chest 1998; 114: 184S-194S.

5. BARST RJ, LOYD JE: Genetics and immunogenetic aspects of primary pulmonary hypertension. Chest 1998; 114: 231S-236S.

6. RICH S, BRAUNWALD E, GROSSMAN W: Pulmonary Hypertension. En: Heart Disease: A Textbook of Cardiovascular Medicine, 5th ed, Braunwald E (ed), Philadelphia, WB Saunders Co, 1997.

7. BARST RJ, RUBIN LJ, LONG WA, MCGOON M, RICH S, BADESH DD, ET AL: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-302.

8. SANDOVAL J, GASPAR J, PULIDO T, BAUTISTA E, MARTÍNEZ-GUERRA ML, ZEVALLOS M, ET AL: Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998; 32: 297-304.